Download PDF
J Knee Surg 2016; 29(06): 443-450
DOI: 10.1055/s-0035-1569481
Original Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Cryopreserved Amniotic Suspension for the Treatment of Knee Osteoarthritis

Jeremy B. Vines
1   Department of Biomedical Engineering, University of Alabama at Birmingham, Birmingham, Alabama
2   NuTech Medical—Research and Development, Birmingham, Alabama
,
Antonios O. Aliprantis
3   Division of Rheumatology, Immunology and Allergy, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts
,
Andreas H. Gomoll
4   Department of Orthopaedic Surgery, Brigham and Women's Hospital, Boston, Massachusetts
,
Jack Farr
5   OrthoIndy—Cartilage Restoration Center, Greenwood, Indiana
› Author Affiliations
Further Information

Publication History

05 May 2015

20 October 2015

Publication Date:
18 December 2015 (online)

    Permissions and Reprints

Abstract

There are few treatment options for symptomatic knee osteoarthritis (OA). Human amniotic suspension allografts (ASA) have anti-inflammatory and chondroregenerative potential and thus represent a promising treatment strategy. In anticipation of a large, placebo-controlled trial of intra-articular ASA for symptomatic knee OA, an open-label prospective feasibility study was performed. Six patients with Kellgren–Lawrence grades 3 and 4 tibiofemoral knee OA were administered a single intra-articular ASA injection containing cryopreserved particulated human amnion and amniotic fluid cells. Patients were followed for 12 months after treatment. No significant injection reactions were noted. Compared with baseline there were (1) no significant effect of the ASA injection on blood cell counts, lymphocyte subsets, or inflammatory markers and (2) a small, but statistically significant increase in serum IgG and IgE levels. Patient-reported outcomes including International Knee Documentation Committee, Knee Injury and Osteoarthritis Outcome, and Single Assessment Numeric Evaluation scores were collected throughout the study and evaluated for up to 12 months. Overall, this study demonstrates the feasibility of a single intra-articular injection of ASA for the treatment of knee OA and provides the foundation for a large placebo-controlled trial of intra-articular ASA for symptomatic knee OA.

Keywords

osteoarthritis - viscosupplementation - amnion - stem cells - allograft
 

  • References

  • 1 From the Centers for Disease Control and Prevention. Prevalence of disabilities and associated health conditions among adults—United States, 1999. JAMA 2001; 285 (12) 1571-1572
    PubMedGoogle Scholar
  • 2 Sokolove J, Lepus CM. Role of inflammation in the pathogenesis of osteoarthritis: latest findings and interpretations. Ther Adv Musculoskelet Dis 2013; 5 (2) 77-94
    CrossrefPubMedGoogle Scholar
  • 3 Little CB, Hunter DJ. Post-traumatic osteoarthritis: from mouse models to clinical trials. Nat Rev Rheumatol 2013; 9 (8) 485-497
    CrossrefPubMedGoogle Scholar
  • 4 Loeser RF, Goldring SR, Scanzello CR, Goldring MB. Osteoarthritis: a disease of the joint as an organ. Arthritis Rheum 2012; 64 (6) 1697-1707
    CrossrefPubMedGoogle Scholar
  • 5 Das A, Neher JO, Safranek S. Clinical inquiries. Do hyaluronic acid injections relieve OA knee pain?. J Fam Pract 2009; 58 (5) 281c-281e
    PubMedGoogle Scholar
  • 6 Kingsbury SR, Hensor EM, Walsh CA, Hochberg MC, Conaghan PG. How do people with knee osteoarthritis use osteoarthritis pain medications and does this change over time? Data from the Osteoarthritis Initiative. Arthritis Res Ther 2013; 15 (5) R106
    CrossrefPubMedGoogle Scholar
  • 7 Raynauld JP, Buckland-Wright C, Ward R , et al. Safety and efficacy of long-term intraarticular steroid injections in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2003; 48 (2) 370-377
    CrossrefPubMedGoogle Scholar
  • 8 Rutjes AW, Jüni P, da Costa BR, Trelle S, Nüesch E, Reichenbach S. Viscosupplementation for osteoarthritis of the knee: a systematic review and meta-analysis. Ann Intern Med 2012; 157 (3) 180-191
    CrossrefPubMedGoogle Scholar
  • 9 Colen S, van den Bekerom MP, Mulier M, Haverkamp D. Hyaluronic acid in the treatment of knee osteoarthritis: a systematic review and meta-analysis with emphasis on the efficacy of different products. BioDrugs 2012; 26 (4) 257-268
    CrossrefPubMedGoogle Scholar
  • 10 Arrich J, Piribauer F, Mad P, Schmid D, Klaushofer K, Müllner M. Intra-articular hyaluronic acid for the treatment of osteoarthritis of the knee: systematic review and meta-analysis. CMAJ 2005; 172 (8) 1039-1043
    CrossrefPubMedGoogle Scholar
  • 11 Campo GM, Avenoso A, Nastasi G , et al. Hyaluronan reduces inflammation in experimental arthritis by modulating TLR-2 and TLR-4 cartilage expression. Biochim Biophys Acta 2011; 1812 (9) 1170-1181
    CrossrefPubMedGoogle Scholar
  • 12 Hirota W. Intra-articular injection of hyaluronic acid reduces total amounts of leukotriene C4, 6-keto-prostaglandin F1alpha, prostaglandin F2alpha and interleukin-1beta in synovial fluid of patients with internal derangement in disorders of the temporomandibular joint. Br J Oral Maxillofac Surg 1998; 36 (1) 35-38
    CrossrefPubMedGoogle Scholar
  • 13 Bush JR, Beier F. TGF-β and osteoarthritis—the good and the bad. Nat Med 2013; 19 (6) 667-669
    CrossrefPubMedGoogle Scholar
  • 14 Aoki CA, Borchers AT, Li M , et al. Transforming growth factor beta (TGF-beta) and autoimmunity. Autoimmun Rev 2005; 4 (7) 450-459
    CrossrefPubMedGoogle Scholar
  • 15 Sawhney CP. Amniotic membrane as a biological dressing in the management of burns. Burns 1989; 15 (5) 339-342
    CrossrefPubMedGoogle Scholar
  • 16 Mermet I, Pottier N, Sainthillier JM , et al. Use of amniotic membrane transplantation in the treatment of venous leg ulcers. Wound Repair Regen 2007; 15 (4) 459-464
    CrossrefPubMedGoogle Scholar
  • 17 Werber B, Martin E. A prospective study of 20 foot and ankle wounds treated with cryopreserved amniotic membrane and fluid allograft. J Foot Ankle Surg 2013; 52 (5) 615-621
    CrossrefPubMedGoogle Scholar
  • 18 Shimberg M. The use of amniotic-fluid concentrate in orthopaedic conditions. J Bone Joint Surg Am 1938; 20 (1) 167-177
    PubMedGoogle Scholar
  • 19 Hao Y, Ma DH, Hwang DG, Kim WS, Zhang F. Identification of antiangiogenic and antiinflammatory proteins in human amniotic membrane. Cornea 2000; 19 (3) 348-352
    CrossrefPubMedGoogle Scholar
  • 20 Litwiniuk M, Grzela T. Amniotic membrane: new concepts for an old dressing. Wound Repair Regen 2014; 22 (4) 451-456
    CrossrefPubMedGoogle Scholar
  • 21 Koh JW, Shin YJ, Oh JY , et al. The expression of TIMPs in cryo-preserved and freeze-dried amniotic membrane. Curr Eye Res 2007; 32 (7–8) 611-616
    CrossrefPubMedGoogle Scholar
  • 22 Lang AK, Searle RF. The immunomodulatory activity of human amniotic fluid can be correlated with transforming growth factor-beta 1 (TGF-beta 1) and beta 2 activity. Clin Exp Immunol 1994; 97 (1) 158-163
    PubMedGoogle Scholar
  • 23 Luo C, Jia W, Wang K , et al. Human amniotic fluid stem cells suppress PBMC proliferation through IDO and IL-10-dependent pathways. Curr Stem Cell Res Ther 2014; 9 (1) 36-45
    PubMedGoogle Scholar
  • 24 Yan WH, Lin A, Chen XJ , et al. Immunological aspects of human amniotic fluid cells: implication for normal pregnancy. Cell Biol Int 2008; 32 (1) 93-99
    CrossrefPubMedGoogle Scholar
  • 25 Jin CZ, Park SR, Choi BH, Lee KY, Kang CK, Min BH. Human amniotic membrane as a delivery matrix for articular cartilage repair. Tissue Eng 2007; 13 (4) 693-702
    CrossrefPubMedGoogle Scholar
  • 26 Meinert M, Eriksen GV, Petersen AC , et al. Proteoglycans and hyaluronan in human fetal membranes. Am J Obstet Gynecol 2001; 184 (4) 679-685
    CrossrefPubMedGoogle Scholar
  • 27 Kim J, Lee Y, Kim H , et al. Human amniotic fluid-derived stem cells have characteristics of multipotent stem cells. Cell Prolif 2007; 40 (1) 75-90
    PubMedGoogle Scholar
  • 28 Kolambkar YM, Peister A, Soker S, Atala A, Guldberg RE. Chondrogenic differentiation of amniotic fluid-derived stem cells. J Mol Histol 2007; 38 (5) 405-413
    CrossrefPubMedGoogle Scholar
  • 29 Rodrigues MT, Lee SJ, Gomes ME, Reis RL, Atala A, Yoo JJ. Bilayered constructs aimed at osteochondral strategies: the influence of medium supplements in the osteogenic and chondrogenic differentiation of amniotic fluid-derived stem cells. Acta Biomater 2012; 8 (7) 2795-2806
    CrossrefPubMedGoogle Scholar
  • 30 Winterstein AP, McGuine TA, Carr KE, Hetzel SJ. Comparison of IKDC and SANE outcome measures following knee injury in active female patients. Sports Health 2013; 5 (6) 523-529
    CrossrefPubMedGoogle Scholar
  • 31 Irrgang JJ, Anderson AF, Boland AL , et al; International Knee Documentation Committee. Responsiveness of the International Knee Documentation Committee Subjective Knee Form. Am J Sports Med 2006; 34 (10) 1567-1573
    CrossrefPubMedGoogle Scholar
  • 32 Di Trapani M, Bassi G, Ricciardi M , et al. Comparative study of immune regulatory properties of stem cells derived from different tissues. Stem Cells Dev 2013; 22 (22) 2990-3002
    CrossrefPubMedGoogle Scholar
  • 33 Krampera M, Glennie S, Dyson J , et al. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 2003; 101 (9) 3722-3729
    CrossrefPubMedGoogle Scholar
  • 34 Abhishek A, Doherty M. Mechanisms of the placebo response in pain in osteoarthritis. Osteoarthritis Cartilage 2013; 21 (9) 1229-1235
    CrossrefPubMedGoogle Scholar
  • 35 Beggs KJ, Lyubimov A, Borneman JN , et al. Immunologic consequences of multiple, high-dose administration of allogeneic mesenchymal stem cells to baboons. Cell Transplant 2006; 15 (8–9) 711-721
    CrossrefPubMedGoogle Scholar
  • 36 Strong DM, Friedlaender GE, Tomford WW , et al. Immunologic responses in human recipients of osseous and osteochondral allografts. Clin Orthop Relat Res 1996; (326) 107-114
    PubMedGoogle Scholar
  • 37 Lucaciu D, Cristea V, Hopulele I, Borz T-S. Humoral immune response after bone grafting. Magy Traumatol Ortop Kezseb Plasztikai Seb 2000; 43 (3) 207-211
    PubMedGoogle Scholar
  • 38 Kaviani A, Perry TE, Dzakovic A, Jennings RW, Ziegler MM, Fauza DO. The amniotic fluid as a source of cells for fetal tissue engineering. J Pediatr Surg 2001; 36 (11) 1662-1665
    CrossrefPubMedGoogle Scholar
  • 39 Kaviani A, Guleserian K, Perry TE, Jennings RW, Ziegler MM, Fauza DO. Fetal tissue engineering from amniotic fluid. J Am Coll Surg 2003; 196 (4) 592-597
    CrossrefPubMedGoogle Scholar
  • 40 Hunt CJ. Cryopreservation of human stem cells for clinical application: a review. Transfus Med Hemother 2011; 38 (2) 107-123
    CrossrefPubMedGoogle Scholar
  • 41 Miranda-Sayago JM, Fernández-Arcas N, Benito C, Reyes-Engel A, Carrera J, Alonso A. Lifespan of human amniotic fluid-derived multipotent mesenchymal stromal cells. Cytotherapy 2011; 13 (5) 572-581
    CrossrefPubMedGoogle Scholar
  • 42 Roubelakis MG, Pappa KI, Bitsika V , et al. Molecular and proteomic characterization of human mesenchymal stem cells derived from amniotic fluid: comparison to bone marrow mesenchymal stem cells. Stem Cells Dev 2007; 16 (6) 931-952
    CrossrefPubMedGoogle Scholar
  • 43 He H, Li W, Tseng DY , et al. Biochemical characterization and function of complexes formed by hyaluronan and the heavy chains of inter-alpha-inhibitor (HC*HA) purified from extracts of human amniotic membrane. J Biol Chem 2009; 284 (30) 20136-20146
    CrossrefPubMedGoogle Scholar
  • 44 Shay E, He H, Sakurai S, Tseng SC. Inhibition of angiogenesis by HC·HA, a complex of hyaluronan and the heavy chain of inter-α-inhibitor, purified from human amniotic membrane. Invest Ophthalmol Vis Sci 2011; 52 (5) 2669-2678
    CrossrefPubMedGoogle Scholar